Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tibulizumab in adults with diffuse cutaneous systemic sclerosis
2024-519335-42-01Phase 2Authorised
- Sponsor
- Zura Bio
- Start
- Dec 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 11
01
Overview
Phase 2, randomised, double-blind trial of tibulizumab in systemic sclerosis (SSc) (3 arms), sponsored by Zura Bio. Planned start Dec 2025; status: authorised.
02
Drugs
tibulizumab
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on 2024-519335-42-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519335-42-01.